UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

arrowhead läuft - zu recht

Seite 10 von 19
neuester Beitrag: 04.12.19 22:11
eröffnet am: 14.02.05 11:14 von: brokeboy Anzahl Beiträge: 472
neuester Beitrag: 04.12.19 22:11 von: macos Leser gesamt: 85327
davon Heute: 37
bewertet mit 3 Sternen

Seite: Zurück 1 | ... | 7 | 8 | 9 |
| 11 | 12 | 13 | ... | 19  Weiter  

2226 Postings, 4088 Tage macosARO-AAT

 
  
    
15.02.18 19:44
Feb 15, 2018
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
http://ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=1057707
 

2226 Postings, 4088 Tage macosARO-AAT

 
  
    
22.02.18 14:00
Feb 22, 2018
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
http://ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=1058336  

2226 Postings, 4088 Tage macosSMI RNA Therapeutics

 
  
    
22.02.18 16:49
Feb 22, 2018
3:10 PM UK
SMI RNA Therapeutics Conference
Location: London
http://files.shareholder.com/downloads/...rowhead_Pharmaceuticals.pdf  

2226 Postings, 4088 Tage macosAsiaTIDES

 
  
    
02.03.18 12:24
Feb 27 - Mar 1, 2018
AsiaTIDES: Oligonucleotide and Peptide Therapeutics

Arrowhead?s TRiM? Delivery System ? Potent, Modular, and Versatile for RNAi Bruce D. Given,
http://ir.arrowheadpharma.com/static-files/...-4cc3-86ee-142fc21906c1


Recent Advances in RNAi Therapeutics at Arrowhead Pharmaceuticals Zhen Li, Ph.D., SVP Chemistry and Manufacturing
Location:
Kyoto, Japan
http://ir.arrowheadpharma.com/static-files/...-44ba-b9bf-b40175cc5017  

2226 Postings, 4088 Tage macosEquity Research Report

 
  
    
08.03.18 14:28
$ARWR vs. $ALNY - @BioBoyScout's Equity Research Report, A Comparative Analysis, March 8, 2018.
https://drive.google.com/file/d/1Q14L9dBLn3hR8hzcUmgzW4ce2I39py4x/view  

2226 Postings, 4088 Tage macoszurück in der Klinik

 
  
    
12.03.18 12:53
March 12, 2018 07:30 AM Eastern Daylight Time

Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
https://www.businesswire.com/news/home/20180312005310/en/  

2226 Postings, 4088 Tage macosRNAi Therapeutics: To the Liver ... and Beyond

 
  
    
19.03.18 11:12

2226 Postings, 4088 Tage macosARO-HBV

 
  
    
27.03.18 13:35

Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
March 27, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/...sing-Phase-12-Study-ARO-HBV  

2226 Postings, 4088 Tage macosJefferies Starts Arrowhead Research (ARWR) at Buy

 
  
    
27.03.18 13:47
March 27, 2018 4:15 AM EDT
Jefferies initiates coverage on Arrowhead Research (NASDAQ: ARWR) with a Buy rating and a price target of $10.00.Analyst Maury Raycroft .
https://www.streetinsider.com/Analyst+Comments/...t+Buy/13986265.html  

2226 Postings, 4088 Tage macosEASL

 
  
    
28.03.18 17:27

Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress?
March 28, 2018 07:30 AM Eastern Daylight Time
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company?s investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and ARO-HBV) and liver disease associated with alpha-1 antitrypsin deficiency (ARO-AAT), at The International Liver Congress? 2018, the annual meeting of the European Association for the Study of the Liver (EASL), being held in Paris from April 11-15, 2018.
https://www.businesswire.com/news/home/...-Liver#.WruBGQGrnSo.twitter  

2226 Postings, 4088 Tage macosARC-520 Clinical Data

 
  
    
11.04.18 14:10

Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress?
April 11, 2018 07:00 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180411005375/en/
Key results include the following:

   One HBeAg-negative patient serocleared HBsAg post ARC-520
   Mild ALT changes off ARC-520 therapy coincided with sustained host responses in 2/3 HBeAg- positive and 2/5 HBeAg-negative patients
   A single dose of ARC-520 in combination with ETV reduced HBsAg for up to 44 weeks
   Multiple doses of ARC-520 resulted in additional HBsAg reductions in all patients by as much 5.3 Log10
   ARC-520 in combination with ETV was effective at rapidly suppressing HBV DNA
 

2226 Postings, 4088 Tage macosWorld Orphan Drug Congress USA 2018

 
  
    
26.04.18 11:05

2226 Postings, 4088 Tage macosARO-Lung1=cystic fibrosis

 
  
    
01.05.18 13:48
Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
https://www.businesswire.com/news/home/20180501005558/en/

American Thoracic Society (ATS) 2018 International Conference ? San Diego, May 18-23, 2018

May 21, 9:15 a.m.-4:15 p.m. PDT ? Erik Bush, Ph.D., Arrowhead?s director of extra-hepatic targeting, will deliver a poster presentation titled, ?Targeting ?ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis.? In this presentation, Dr. Bush will present new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, targeting the epithelial sodium channel alpha subunit (?ENaC) for the treatment of cystic fibrosis.  

2226 Postings, 4088 Tage macosQ2 2018 Results Earnings Conference Call May 8,

 
  
    
09.05.18 10:44
Arrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Fiscal Q2 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/...cal-q2-2018-results-earnings-call  

16986 Postings, 3529 Tage Balu4uPassend zum Threadtitel

 
  
    
09.05.18 16:44

2226 Postings, 4088 Tage macosThe Pharmaceutical Journal 17 MAY 2018

 
  
    
19.05.18 13:53

2226 Postings, 4088 Tage macosARO-ENaC

 
  
    
1
21.05.18 16:45

Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
May 21, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180521005437/en/  

2226 Postings, 4088 Tage macos6 Konferenzen im Juni

 
  
    
30.05.18 13:46

Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
May 30, 2018 07:25 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180530005534/en/  

2226 Postings, 4088 Tage macosARO-HBV

 
  
    
30.05.18 14:11

Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
May 30, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180530005538/en/  

2226 Postings, 4088 Tage macosARO-AAT

 
  
    
18.06.18 16:01

Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
June 18, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180618005327/en/

Two planned cohorts at a dose of 400 mg were eliminated because maximal activity appeared to occur at lower doses than expected.  

2226 Postings, 4088 Tage macosARO-AAT

 
  
    
27.06.18 13:52

Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

June 27, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180627005432/en/  

2226 Postings, 4088 Tage macosNew Clinical Data on ARO-AAT

 
  
    
29.06.18 14:53

Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
June 29, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180629005141/en/  

2226 Postings, 4088 Tage macosMilestone Payment from Amgen

 
  
    
1
01.08.18 13:58
Arrowhead Pharmaceuticals Earns $10 Million Milestone Payment from Amgen
August 01, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/...0-Million-Milestone-Payment

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease. AMG 890 is an RNAi therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease.  

2226 Postings, 4088 Tage macosArtikel

 
  
    
1
02.08.18 20:04

https://madison-com.cdn.ampproject.org/v/s/...-b8ac-9a3f9f42ba26.html
Auszug

Arrowhead plans to seek federal regulatory approval to start clinical trials on three more products before the end of the year. Two are cardiometabolic ? referring to cardiovascular disease and diabetes ? and one targets cystic fibrosis, said Vincent Anzalone, vice president of finance and investor relations. A prospective drug against kidney cancer is on the agenda for 2019 and there is ?a handful of others beyond that,? he said, all built on the targeted RNAi molecule platform.

 

Seite: Zurück 1 | ... | 7 | 8 | 9 |
| 11 | 12 | 13 | ... | 19  Weiter  
   Antwort einfügen - nach oben